Trial · NCT04323527
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality rate reduction of 50% by day 28 | 28 days after randomization | proportion of deaths at day 28 between groups compared |
| Secondary | Absolute mortality on days 7 and 14 | 7 and 14 days after first dose | number of deaths at days 7 and 14 between groups compared |
| Secondary | Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28 | 14 and 28 days after first dose | clinical status |
| Secondary | Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization | during and after intervention, up to 28 days | clinical status |
| Secondary | Duration of supplemental oxygen (if applicable) | during and after intervention, up to 28 days | supplemental oxygen |
| Secondary | Duration of mechanical ventilation (if applicable) | during and after intervention, up to 28 days | mechanical ventilation |
| Secondary | Absolute duration of hospital stay in days | during and after intervention, up to 28 days | hospitalization |
| Secondary | Prevalence of grade 3 and 4 adverse events | during and after intervention, up to 28 days | adverse events grade 3 and 4 |
| Secondary | Prevalence of serious adverse events | during and after intervention, up to 28 days | adverse events |
| Secondary | Change in serum creatinine level | during and after intervention, up to 28 days | increase or decrease in serum creatinine compared to baseline |
| Secondary | Change in serum troponin I level | during and after intervention, up to 28 days | increase or decrease in serum troponin I compared to baseline |
| Secondary | Change in serum aspartate aminotransferase level | during and after intervention, up to 28 days | increase or decrease in serum aspartate aminotransferase compared to baseline |
| Secondary | Change in serum CK-MB level | during and after intervention, up to 28 days | increase or decrease in serum aspartate aminotransferase compared to baseline |
| Secondary | Change in detectable viral load in respiratory tract swabs | during and after intervention, up to 28 days | virus clearance from respiratory tract secretion |
| Secondary | Viral concentration in blood samples | during and after intervention, up to 28 days | viremia in blood detected through RT-PCR |
| Secondary | Absolute number of causes leading to participant death (if applicable) | during and after intervention, up to 28 days | death |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04323527/registered